What is Arecor?
Arecor is a specialized biopharmaceutical firm dedicated to the advancement of drug development and delivery, with a primary focus on diabetes and other cardiometabolic conditions. At the core of its operations is the proprietary Arestat technology platform, which enables the creation of enhanced therapeutic medicines. By optimizing the stability and delivery of complex proteins and peptides, Arecor addresses significant unmet needs in patient care. The company operates through a collaborative business model, partnering with established pharmaceutical and medtech entities to bring innovative treatments to market. With a robust intellectual property portfolio, Arecor is well-positioned to disrupt traditional treatment paradigms, ensuring that its clinical-stage assets are backed by rigorous scientific validation and strategic commercial partnerships.
How much funding has Arecor raised?
Arecor has raised a total of $8M across 2 funding rounds:
Private Equity
$230K
Unspecified
$7.8M
Private Equity (2015): $230K with participation from Hygea VCT Plc
Unspecified (2018): $7.8M led by Downing, Albion Capital Group, and Calculus Capital
Key Investors in Arecor
Albion Capital Group
AlbionVC is the technology investment arm of Albion Capital Group LLP, managing approximately 1 billion in venture funds and supporting visionary founders with long-term capital and scale-up expertise.
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on high-growth technology and healthcare businesses.
Downing
Founded in 1986, Downing is a financial services company headquartered in London that designs and manages diverse investment products for institutional and private clients.
What's next for Arecor?
With the recent influx of capital, Arecor is poised to transition its lead candidates through critical clinical milestones. The strategic focus remains on expanding the utility of the Arestat platform, potentially broadening its application beyond diabetes into other therapeutic areas where protein stability is a limiting factor. As the company moves toward later-stage clinical trials, the emphasis will likely shift toward commercialization readiness and the strengthening of its global partnership network. Investors are closely monitoring the company's ability to translate its technological advantages into tangible clinical outcomes, which will be the primary driver for future valuation growth and potential market entry. The firm's commitment to maintaining a lean, high-impact R&D model suggests a continued focus on high-value licensing agreements and strategic alliances.
See full Arecor company page
